芦可替尼介导的矛盾性JAK2超磷酸化源于激活环酪氨酸免受磷酸酶作用
骨髓纤维化中约50%由JAK2激活突变驱动,多为V617F。芦可替尼治疗后JAK2-V617F细胞出现激活环Tyr1007/Tyr1008矛盾性超磷酸化。研究发现该现象为内在机制,芦可替尼使激活环构象稳定从而保护磷酸化位点免受磷酸酶作用,药物解离后超磷酸化JAK2显示STAT5靶基因PIM激酶过度反弹激活。
要点
- 芦可替尼处理JAK2-V617F细胞引起激活环Tyr1007/Tyr1008矛盾性超磷酸化。
- 耐药突变JAK2-V617F+L983F和激酶失活突变JAK2-V617F+K882R不出现该超磷酸化。
- 芦可替尼使激活环埋藏于激酶结构域内,保护pTyr1007/1008免受磷酸酶作用。
核心结论
- 芦可替尼通过诱导构象变化使JAK2激活环稳定,保护pTyr1007/1008免受磷酸酶作用,导致矛盾性超磷酸化。
- 药物解离后超磷酸化JAK2显示STAT5靶基因PIM激酶的过度反弹激活。
- 结果提示芦可替尼通过构象变化调节激酶活性是一种新的激酶调控模式。
研究设计与样本
- 研究使用JAK2-V617F表达细胞、芦可替尼耐药JAK2变体(V617F+L983F)和激酶失活突变体(JAK2-V617F+K882R)进行机制探索。
- 采用抗pYyr1007/1008抗体免疫沉淀、Arg975和Lys999突变为Ala等实验方法。
- 原文未报告样本量、研究类型等设计细节。
主要发现
- 芦可替尼处理JAK2-V617F表达细胞引起JAK2激活环Tyr1007/Tyr1008矛盾性超磷酸化。
- 耐药变体JAK2-V617F+L983F和激酶失活突变体JAK2-V617F+K882R在芦可替尼处理后不显示矛盾性超磷酸化。
- 抗pTyr1007/1008抗体在芦可替尼存在下未能免疫沉淀天然JAK2-V617F,尽管该位点已超磷酸化。
- Arg975和Lys999突变为Ala降低了Tyr1007/Tyr1008磷酸化,且芦可替尼处理未导致JAK2超磷酸化。
- 芦可替尼解离后超磷酸化JAK2显示STAT5靶基因PIM激酶的过度反弹激活。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) in 50% of cases is driven by an activating JAK2 mutation, mostly V617F. Ruxolinitib is approved for the treatment of MF. Responses to ruxolitinib in MF are of limited duration. Unexpectedly, treatment of JAK2-V617F expressing cells with ruxolitinib causes paradoxical hyperphosphorylation of JAK2 at activation loop Tyr1007/Tyr1008. The significance of ruxolitinib-induced JAK2 hyperphosphorylation is not well understood. We found that a ruxolitinib-resistant JAK2 variant (V617F + L983F) and a kinase dead mutant (JAK2-V617F + K882R) did not show paradoxical hyperphosphorylation after ruxolitinib treatment indicating that it is an intrinsic mechanism. Antibodies against pTyr1007/1008 failed to immunoprecipitate native JAK2-V617F in the presence of ruxolitinib, although JAK2-V617F was hyperphosphorylated at these sites, suggesting that in the presence of ruxolitinib the JAK2 activation loop is buried within the kinase domain. This stabilization of the activation loop conformation resulted in the protection of pTyr1007/1008 sites from phosphatases. Mutation of Arg975 and Lys999 to Ala reduced the phosphorylation at both Tyr1007/Tyr1008 residues, and notably, ruxolitinib treatment did not lead to JAK2 hyperphosphorylation. Importantly, hyperphosphorylated JAK2 after ruxolitinib dissociation displayed excess rebound activation of STAT5 target gene PIM kinase. Our results suggest a novel mode of kinase regulation by modulating kinase activity through conformational changes induced by ruxolitinib.Subject categories: JAK2-V617F, Ruxolitinib, JAK2 hyperphosphorylation, Phosphatases action, PIM kinases.
引用
- Gorantla SP, Oelschläger L, Prince G, et al. Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases. Leukemia. 2025. PMID: 40269271. doi:10.1038/s41375-025-02594-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。